<DOC>
	<DOC>NCT02945163</DOC>
	<brief_summary>Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.</brief_summary>
	<brief_title>Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV antibody positive Chinese nationality Na√Øve to antiretroviral therapy Willing to start antiretroviral therapy Provision of written informed consent Pregnant, breastfeeding, or lactating Females try to get pregnant during the research period Subjects who allergic to any of the research drugs Subjects that taking other drugs that known to impact the absorption, distribution, metabolism and excretion of the research drugs Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. This would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol Laboratory blood values: Haemoglobin &lt;9.0 grams/decilitre (g/dL) Neutrophil count &lt;1500/mm3 Platelet count &lt;75,000/mm3 Aspartate aminotransferase or Alanine transaminase &gt;3 times Upper Limit of Normal (ULN) Total bilirubin &gt;3 times Upper Limit of Normal (ULN) Subjects with an estimated creatinine clearance of &lt;90 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>